Enzyme-linked immunosorbent assays using virus-like particles containing mutations of conserved residues on envelope protein can distinguish three flavivirus infections

Wen-Yang Tsai, Kaitlin Driesse, Jih-Jin Tsai, Szu-Chia Hsieh, Robert Sznejder Granate, Olivia Jenkins, Gwong-Jen Chang and Wei-Kung Wang

ABSTRACT
The recent outbreaks of Zika virus (ZIKV) in flavivirus-endemic regions highlight the need for sensitive and specific serological tests. Previously we and others reported key fusion loop (FL) residues and/or BC loop (BCL) residues on dengue virus (DENV) envelope protein recognized by flavivirus cross-reactive human monoclonal antibodies and polyclonal sera. To improve ZIKV serodiagnosis, we employed wild type (WT) and FL or FL/BCL mutant virus-like particles (VLP) of ZIKV, DENV1 and West Nile virus (WNV) in enzyme linked immunosorbent assays (ELISA), and tested convalescent-phase serum or plasma samples from reverse-transcription PCR-confirmed cases with different ZIKV, DENV and WNV infections. For IgG ELISA, ZIKV WT-VLP had a sensitivity of 100% and specificity of 52.9%, which was improved to 83.3% by FL/BCL mutant VLP and 92.2% by the ratio of relative optical density of mutant to WT VLP. Similarly, DENV1 and WNV WT-VLP had a sensitivity/specificity of 100%/70.0% and 100%/56.3%, respectively; the specificity was improved to 93.3% and 83.0% by FL mutant VLP. For IgM ELISA, ZIKV, DENV1 and WNV WT-VLP had a sensitivity/specificity of 93.7%–99.3% by FL or FL/BCL mutant VLP. An algorithm based on a combination of mutant and WT-VLP IgG ELISA is proposed to discriminate primary ZIKV, DENV and WNV infections as well as secondary DENV and ZIKV infection with previous DENV infections; this could be a powerful tool to better understand the seroprevalence and pathogenesis of ZIKV in regions where multiple flaviviruses co-circulate.

ARTICLE HISTORY
Received 17 March 2020; Revised 14 July 2020; Accepted 14 July 2020

KEYWORDS
Zika virus; flavivirus; virus-like particles; serodiagnosis; fusion loop

Introduction
Although the transmission of Zika virus (ZIKV) in the Americas has greatly declined since late 2017, the concerns of congenital Zika syndrome (CZS) and its potential re-emergence in flavivirus-endemic regions underscore the need for sensitive and specific diagnostic tests [1,2]. Based on the guidelines from the US Centers for Disease Control and Prevention, a positive nucleic acid test as soon as possible post-symptom onset (PSO) can confirm ZIKV infection, and a negative IgM test can exclude ZIKV infection [3]. Most (~80%) ZIKV infections are asymptomatic; ZIKV can be transmitted following asymptomatic infection or through sexual contact [1,2]. Moreover, many individuals test for ZIKV infection beyond the period when RNA is detectable, thus serological tests remain as a critical component of ZIKV diagnosis [1–3].

In the genus Flavivirus of the family Flaviviridae, several mosquito-borne viruses belonging to different serocomplexes cause significant human diseases, including the four serotypes of dengue virus (DENV) in the DENV serocomplex, West Nile virus (WNV) and Japanese encephalitis virus (JEV) in the JEV serocomplex, yellow fever virus (YFV) as a single member, and ZIKV [4]. The envelope (E) protein, present on the surface of virions, is the major target of antibody response following flavivirus infection [4]. Traditional serological tests have been developed using recombinant E protein, inactivated virions or virus-like particles (VLP) [4–6]. However, these E protein-based serological tests are hampered by cross-reactivity among different flaviviruses. Thus, positive or equivocal results of IgM tests require further testing with time-consuming plaque reduction neutralization tests.
BCL residues (such as T76, Q77, G78 and E79) as epiternal key FL residues (such as W101 and F108) and/or serological tests [11] contribute to the cross-reactivity of E protein-based challenge for seroprevalence study. The second durability of anti-NS1 antibodies in serum remains a shown improved specifici-
city [26–32]. However, the durability of anti-NS1 antibodies in serum remains a challenge for seroprevalence study. The second approach is to use recombinant domain III (DIII) as antigen; one study reported reduced cross-reactivity by recombinant DIII of ZIKV and DENV2, but not for secondary DENV (sDENV) infection during early convalescence [33]. Another approach is to use FL-and/or BCL-mutated recombinant E protein or VLP as antigen. Previous studies using such approach have reported reduced cross-reactivity for DENV, WNVR, JEV and ZIKV in ELISA [20,21,34–36], nonetheless, the assays developed from these studies primarily targeted one or two flaviviruses. Another study using FL/BCL-mutated recombinant E proteins of ZIKV and DENV1-4 showed improved specificity in IgM ELISA, however, cross reactivity in IgG ELISA remains, which requires pre-incubation with large amounts of heterologous recombinant E protein to reduce [37].

After the ZIKV outbreak in the Americas, several questions remain unanswered such as its surveillance, seroprevalence and interactions with other flaviviruses in endemic regions [2,3]. Recent studies have shown that DENV- or WNVR-immune sera enhanced ZIKV replication in vitro and in mice [38–43]. However, such enhancement was not observed in non-human primates, highlighting the importance of more human studies in the field [44]. Two cohort studies reported that prior DENV infection was associated with decreased risk of symptomatic ZIKV infection [45,46]. To advance this area of research, serological tests that can discriminate different DENV and ZIKV infections including primary DENV, sDENV, pZIKV and ZIKV infection with previous DENV (ZIKVwp-DENV) infections, as well as other flavivirus infections are critically needed to better understand the epidemiology and pathogenesis of ZIKV in endemic regions.

In this study, we employed wild type (WT) and FL or FL/BCL mutant VLP of ZIKV, DENV1 and WNVR to develop IgG and IgM ELISA and investigated convalescent- and post-convalescent-phase serum or plasma samples from reverse transcription-PCR (RT–PCR) confirmed cases with different ZIKV, DENV and WNVR infections. We found that FL or FL/BCL mutant VLP and the ratio of relative optical density (rOD) of mutant to WT VLP can improve the specificity of IgG ELISA, and proposed an algorithm to discriminate three flavivirus infections.

Materials and methods

Ethics statement and human samples

The study was approved by the Institutional Review Board (IRB) of the University of Hawaii (CHS #17568, CHS#23786). The numbers, serotypes, sampling time and sources of different panels of serum or plasma samples are summarized in Table S1. Samples collected <3 or ≥3 months PSO were designated as convalescent- or post-convalescent-phase samples, respectively; for pDENV1 panel < or ≥4 months was used to separate the two subgroups with comparable samples size. Samples from RT–PCR confirmed Zika cases were from the Pediatric Dengue Cohort Study and the Pediatric Dengue Hospital-based Study in Managua, Nicaragua between July 2016 and March 2017 as described previously [47,48]. These studies were approved by the IRBs of the University of California, Berkeley, and Nicaraguan Ministry of Health. Thirty-six plasma samples from blood donors, who were WNVR-positive by the transcription-mediated amplification, IgM and IgG antibody tests
between 2006 and 2015, were designated as pWNV infection panel and provided by the American Red Cross at Gaithersburg, Maryland [49]. Samples from RT–PCR confirmed cases with pDENV1 or sDENV infection were from Taiwan, Hawaii and Nicaragua prior to the 2015–2016 Zika outbreak; 66 flavivirus-naïve samples from a seroprevalence study were included as control [10,50–52]. pDENV1 or sDENV infection was determined by IgM/IgG ratio or focus-reduction neutralization tests as described previously [50–52].

**Generation of plasmid constructs and VLP**

The plasmids expressing WT premembrane (prM)/E proteins of DENV1 (Hawaii strain) and prM/E proteins with two key FL mutations (W101A and F108A) have been described previously [10,11]. The plasmids expressing WT prM/E proteins of WNV (NY99 strain), ZIKV (PRVABC59 strain), and ZIKV (MR766 strain) were generated by cDNA synthesis using RNA extracted from culture supernatants, followed by PCR as described previously [10,11]. After digestion with KpnI and NotI, the PCR products were cloned into respective sites of pCB vector. Plasmids containing FL mutations and/or BCL mutations were generated by polymerase incomplete primer extension PCR method with two reverse primers overlapping on the mutation sites [53]. After PCR, reaction mixtures were directly transformed into DH5α competent cells for selection. Table S1 summarizes the plasmids generated in this study. All constructs were confirmed by sequencing the entire inserts to rule out second site mutations. The sequences of primers used will be provided upon request.

To generate VLP, 293 T cells (1 × 10⁵ cells) were transfected with 10 μg of plasmid DNA. At 48 h, culture supernatants were collected, clarified by centrifugation at 1250 × g for 20 min, filtered through a 0.22 μm pore-sized membrane (Sartorius), layered over a 20% sucrose buffer, and ultracentrifuged at 65,000 × g at 4°C for 5 h to obtain pellets containing VLP, which were resuspended in 30 μl TNE buffer [10,11].

**IgG and IgM ELISA**

WT and mutant VLP were subjected to serial two-fold dilutions (1:200 to 1:6400), coated on 96-well plates and tested with positive control serum to determine the titre, which was the highest dilution to reach optical density (OD) of 1. For IgG ELISA, the titrated WT and mutant VLP (such as 1:1600) were coated onto 96-well plates at 4°C overnight, followed by blocking (Starting-Block buffer, Thermo Scientific, Waltham, MA), incubation with primary antibody (serum or plasma at 1:400) and secondary antibody (anti-human IgG conjugated with horseradish peroxidase, Jackson Immune Research Laboratory, West Grove, PA), and wash [30,31]. After adding tetramethylbenzidine substrate (Thermo Scientific, Waltham, MA) and stop solution, the OD at 450 nm was read with a reference wavelength of 630 nm. Each ELISA plate included two positive controls (confirmed-ZIKV, DENV or WNV infection), four negative controls (flavivirus-naïve), and samples (all in duplicate). The OD values were divided by the mean OD value of one positive control (OD close to 1) in the same plate to calculate the rOD values for comparison between plates [30,31]. The cutoff rOD of each plate was the mean rOD value of negatives plus 12 standard deviations, which gave a confidence level of 99.9% from 4 negatives [54]; the mean cutoff rOD of all plates for the same antigen was used as the final cutoff rOD. Each ELISA was performed twice (each in duplicate). IgM ELISA was performed similarly except each sample was incubated with Gullsorb reagent (Meridian Bioscience), an IgG absorbent, for 10 min before adding to wells [30,31].

**Statistical analysis**

Two-tailed Mann–Whitney test was used to determine the P values between two groups, and the receiver-operating characteristics (ROC) analysis the cutoffs of the rOD ratios (GraphPad Prism 6). The 95% confidence interval (CI) was calculated by Excel.

**Results**

**WT and FL or FL/BCL mutant VLP**

We first generated two ZIKV VLP (based on PRVABC59 and MR766 strains) and tested with pZIKV, primary WNV (pWNV) and primary DENV1 (pDENV1) infection panels in IgG ELISA. In agreement with the notion that different ZIKV strains belong to a single serotype [55], comparable detection rates and rOD values were found between ZIKV VLP derived from the two strains (Figure S1). ZIKV VLP derived from the PRVABC59 strain, designated as ZIKV WT-VLP, which was close to the circulating strain, was chosen for this study. To determine if FL alone or FL/BCL mutations can reduce the cross-reactivity, we tested ZIKV WT-VLP, FL-VLP containing key FL mutations (W101A and F108A), and FL/BCL-VLP containing FL (W101A and F108A) and 3 BCL (T76A, Q77A and G78A) mutations. Compared with WT- and FL-VLP, FL/BCL-VLP greatly reduced the cross-reactivity from the pWNV panel (6/36 positive vs 28/36 and 11/36 positive) (Figure S2(A–C)). We also generated FL/4BCL-VLP, which contained additional BCL residue mutation (E79A) but did not further reduced cross-reactivity (Figure S2(D–E)).
Due to its low expression, FL/4BCL-VLP was not used. For DENV1 and WNV VLP, initial testing revealed significant reduction of cross-reactivity by FL-VLP; thus, DENV1 and WNV FL-VLP were used in this study (Table S2). We have also examined serial dilutions of each mutant-VLP in comparison with WT-VLP (ZIKV FL/BCL-VLP vs WT-VLP, DENV1 FL-VLP vs WT-VLP, and WNV FL-VLP vs WT-VLP) and their binding to different antibodies in IgG ELISA. The comparable binding of mutant- and WT-VLP at similar dilutions to different flavivirus-immune sera and mAbs except the FL mAbs suggested that each mutant-VLP was expressed well and maintained the overall antigenic structure (Figure S3). However, the quaternary structure of mutant-VLP cannot be assessed due to the lack of using quaternary epitope mAbs.

Reduction of cross-reactivity of ZIKV and DENV1 IgG ELISA by FL or FL/BCL VLP and the rOD ratio of mutant to WT VLP

We next tested IgG ELISA of ZIKV WT-VLP with different panels, including pWNV, pDENV1, pZIKV, ZIKVwprDENV and sDENV infections as well as flavivirus-naïve samples. Compared with flavivirus-naïve
panel, ZIKV WT-VLP can be recognized by both ZIKV (pZIKV and ZIKVwprDENV) and non-ZIKV (pWNV, pDENV1 and sDENV) samples (Figure 1(A)). The cross-reactivity from pWNV and pDENV1 panels was greatly reduced by FL/BCL-VLP (Figure 1(C)). Based on the ROC analysis, we used the ratio of rOD of mutant to WT VLP and compared between ZIKV and non-ZIKV panels to determine a cutoff of 0.57, in which the cross-reactivity from non-ZIKV panels was further reduced (Figure 1(E)). Interestingly, the ZIKVwprDENV and sDENV panels can be discriminated with a sensitivity/specificity of 86.7%/85%. Similar trend was observed for DENV1 IgG ELISA in that the cross-reactivity to WT-VLP from pWNV and pZIKV panels was greatly reduced by FL-VLP and by the rOD ratio of mutant to WT VLP with a cutoff of 0.66 (Figures 1(B, D, F)). Notably, the detection rate for ZIKVwprDENV panel was decreased by the rOD ratio, suggesting reduced recognition of DENV1 FL-VLP by some ZIKVwprDENV samples.

Reduction of cross-reactivity of ZIKV and DENV1 IgM ELISA by FL or FL/BCL VLP

We further tested IgM ELISA with different panels of convalescent-phase samples. Compared with IgG ELISA in Figure 1(A), ZIKV WT-VLP in IgM ELISA were recognized mainly by ZIKV samples (pZIKV

---

**Figure 2.** Results of ZIKV and DENV1 VLP IgM ELISA. Convalescent-phase samples from different panels were tested with ZIKV (A,C,E) and DENV1 (B,D,F) VLP IgM ELISA. (A,B) WT-VLP, (C,D) FL/BCL- or FL-VLP, (E,F) rOD ratio of mutant to WT VLP. Data are the means of two experiments (each in duplicate). Dashed lines indicate cutoff rOD and dotted lines cutoff rOD ratio in panels E and F.
and ZIKVwprDENV) with cross-reactivity to a few non-ZIKV samples (1 pWNV, 2 pDENV1 and 2 sDENV) (Figure 2(A)), which was slightly reduced by ZIKV FL/BCL-VLP or by the rOD ratio with a cutoff of 0.51 (Figure 2(C, E)). Similarly, compared with IgG ELISA in Figure 1(B), DENV1 WT-VLP in IgM ELISA were recognized mainly by DENV samples (pDENV1, sDENV) with some cross-reactivity to non-DENV or non-recent DENV samples (3 pWNV, 3 pZIKV and 5 ZIKVwprDENV) (Figure 2(B)); the cross-reactivity was slightly reduced by DENV1 FL-VLP but not by the rOD ratio with a cutoff of 0.39 (Figure 2(D, F)).

Reduction of cross-reactivity of WNV IgG and IgM ELISA by FL VLP

We next tested IgG and IgM ELISA of another flavivirus, WNV. The cross-reactivity to WNV WT-VLP IgG ELISA from pZIKV and pDENV1 panels was reduced by WNV FL-VLP or by the rOD ratio with a cutoff of 0.50 (Figure 3(A, C, E)), however, considerable cross-reactivity from panels with repeated flavivirus infection (sDENV and ZIKVwprDENV) remains (Figure 3(C, E)). Compared with IgG ELISA, WNV WT-VLP in IgM ELISA were recognized mainly by pWNV samples with some cross-reactivity to non-

Figure 3. Results of WNV VLP IgG and IgM ELISA. Convalescent- and post-convalescent-phase samples from different panels were tested with WNV VLP IgG ELISA (A,C,E), and convalescent-phase samples with WNV VLP IgM ELISA (B,D,F). (A,B) WT-VLP, (C,D) FL-VLP, and (E,F) rOD ratio of mutant to WT VLP. Data are the means of two experiments (each in duplicate). Dashed lines indicate cutoff rOD and dotted lines cutoff rOD ratio in panels E and F.
Table 1. Sensitivity and specificity of different VLP-IgG ELISA.

| ELISA* | Overall | % Sensitivity (95% CI)b | % Specificity (95% CI)b |
|--------|---------|-------------------------|-------------------------|
| ZIKV WT-VLP | 100 (100–100) | 52.9 (44.6–57.2) | naïve:98.5, pZIKV:100, pDENV1:100, pWNV:22.2 |
| ZIKV FL/BCL-VLP | 100 (100–100) | 83.3 (77.1–86.5) | naïve:100, pDENV1:93.8, sDENV:20.0, pWNV:83.3 |
| DENV1 WT-VLP | 100 (100–100) | 92.2 (85.6–95.5) | naïve:NA, pDENV1:93.8, sDENV:85.0, pWNV:96.4 |
| DENV1 FL-VLP | 100 (100–100) | 93.3 (88.9–95.6) | naïve:100, pZIKV94.4, pWNV:80.1 |
| WNV WT-VLP | 100 (100–100) | 91.4 (82.2–96.2) | naïve:NA, pZIKV100, pWNV:82.4 |
| WNV FL-VLP | 100 (100–100) | 83.0 (76.6–86.2) | naïve:100, pZIKV100, pDENV1:93.8, sDENV:30.0 |
| rOD ratio ≥0.57 (ZIKV FL/BCL to WT VLP) | Overall | 92.8 (91.7–100) | naïve:95.8, pZIKV:0, pWNV:52.8 |
| rOD ratio ≥0.66 (DENV1 FL to WT VLP) | Overall | 95.6 (95.5–98.1) | naïve:98.5, pZIKV:0, pWNV:52.8 |
| rOD ratio ≥0.50 (WNV FL to WT VLP) | Overall | 66.1 (54.0–72.3) | naïve:NA, ZIKV100, pDENV1:93.8, sDENV:36.8 |

*BCL: BC loop; CI, confidence interval; ELISA: enzyme-linked immunosorbent assays; FL: fusion loop; NA: not applicable; pDENV1: primary dengue virus type 1 infection; pWNV: primary West Nile virus infection; pZIKV: primary Zika virus infection; rOD: relative optical density; sDENV: secondary dengue virus infection; Sens: sensitivity; Spec: specificity; VLP: virus-like particles; WT: wild type; ZIKVwprDENV: Zika virus infection with previous dengue virus infection.

*For simplicity, the 95% CIs in the subgroup are not shown.

*Compared to that of WT-VLP, the improved specificity by FL-VLP, FL/BCL-VLP or rOD ratio is bolded.

WNV samples (5 pDENV1, 2 pZIKV, 3 ZIKVwprDENV and 1 sDENV) (Figure 3(B)); the cross-reactivity was slightly reduced by WNV FL-VLP or by the rOD ratio with a cutoff of 0.79 (Figure 3(D, F)).

**Sensitivity and specificity**

Table 1 summarizes the sensitivity and specificity of different IgG ELISA. Comparing WT- and FL- or FL/BCL-VLP ELISA, the overall sensitivity is high (100%). The specificity of WT-VLP ELISA (52.9 to 70.0%) were lower than that of FL- or FL/BCL-VLP ELISA (83.0 to 93.3%). The specificity of ZIKV WT-VLP ELISA (52.9%) was improved to 83.3% by FL/BCL-VLP and to 92.2% by the rOD ratio of mutant to WT VLP. Similarly, the specificity of DENV1 WT-VLP ELISA (70.0%) was improved to 93.3% and 91.4% by FL-VLP and the rOD ratio, respectively. For WNV WT-VLP ELISA, the specificity (56.3%) was improved to 83.0% by FL-VLP and to a less extent to 66.1% by the rOD ratio, probably due cross-reactivity from panels with repeated flavivirus infections (sDENV and ZIKVwprDENV) as described above.

Table 2 summarizes the sensitivity and specificity of different IgM ELISA. The sensitivity of ZIKV WT-VLP for pZIKV panel (100%) was higher than that for ZIKVwprDENV panel (75%), suggesting higher sensitivity of IgM ELISA for primary infection. Similarly, the sensitivity of DENV1 WT-VLP for pDENV1 panel (100%) was higher than that for sDENV panel (70.8%). Comparing WT- and FL- or FL/BCL-VLP IgM ELISA, the sensitivity for primary infection panels (pZIKV, pDENV1 and pWNV) is high (91.7 to 100%). The overall specificity of IgM ELISA (91.4 to 99.3%) is higher than that of IgG ELISA (52.9 to 93.3%). Interestingly, the specificity IgM ELISA based on WT-VLP was improved by FL- or FL/BCL-VLP, from 96.4% to 99.3%, 92.3% to 95.8%, and 91.4% to 93.7% for ZIKV, DENV1 and WNV, respectively. The specificity of IgM ELISA was not improved by the rOD ratio.

**Discussion**

In this study, we utilized WT and FL or FL/BCL mutant VLP to develop IgG and IgM ELISA to detect three flavivirus infections, and found that mutant VLP and the rOD ratio of mutant to WT VLP greatly reduced the cross-reactivity and improved the specificity of IgG ELISA. Mutant VLP further improved the specificity of IgM ELISA. These findings have tremendous implications for E protein-based serodiagnosis and serosurveillance in regions where multiple flaviviruses co-circulate.

For IgG ELISA, we propose to use a combination of WT and FL or FL/BCL mutant VLP to distinguish ZIKV, DENV and WNV infections. Figure 4 depicts an algorithm, in which the results of mutant VLP (ZIKV, DENV1 and WNV) will be first analyzed to identify primary DENV, pZIKV and pWNV infections,
followed by the rOD ratio of ZIKV mutant to WT-VLP to discriminate ZIKVwprDENV and sDENV infections. Based on Figure 1(E), the rOD ratio of ZIKV mutant VLP to WT-VLP with a cutoff of 0.57 can distinguish ZIKVwprDENV and sDENV panels; the sensitivity/specificity was 86.7%/85% comparing these two panels and 93.9%/92.2% including other panels (Table 1). This is highly relevant to seroprevalence study in regions where both DENV and ZIKV are prevalent. Notably, the rOD ratios of DENV1 and WNV mutant VLP to WT-VLP were not recommended due to their lower sensitivity/specificity (88.2/91.4% for DENV1 and 100/66.1% for WNV) compared with mutant VLP (Table 1).

For IgM ELISA, FL or FL/BCL mutant VLP can improve the specificity of WT VLP from 91.4−96.4% to 93.7−99.3% while maintaining a high sensitivity (91.7−100%) for primary infection panels (pZIKV, Table 2.

| ELISA | % Sensitivity (95% CI) | % Specificity (95% CI) |
|-------|------------------------|------------------------|
| ZIKV WT-VLP | Overall: 87.5 (77.3–92.7) | 96.4 (93.3–98.0) |
| Subgroup: | pZIKV:100, ZIKVwprDENV:75.0 | naive:100, pDENV1:83.3, sDENV91.7, pWNV:97.2 |
| ZIKV FL/BCL-VLP | Overall: 90.0 (80.7–94.7) | 99.3 (97.9–100) |
| Subgroup: | pZIKV:100, ZIKVwprDENV:80.0 | naive:100, pDENV1:100, sDENV95.8, pWNV:100 |
| rOD ratio ≥0.51 (ZIKV FL/BCL to WT VLP) | Overall: 100 (100–100) | 80.0 (49.9–97.9) |
| Subgroup: | pZIKV:100, ZIKVwprDENV:100 | naive:N/A, pDENV1:100, sDENV50.0, pWNV:100 |
| DENV1 WT-VLP | Overall: 80.6 (67.6–87.2) | 92.3 (87.9–94.5) |
| Subgroup: | pDENV1:100, sDENV:70.8 | naive:100, ZIKVwprDENV:75.0 pZIKV:85.0, pWNV:91.7 |
| DENV1 FL-VLP | Overall: 75.0 (60.9–82.2) | 95.8 (92.5–97.5) |
| Subgroup: | pDENV1:91.7, sDENV:66.7 | naive:100, ZIKVwprDENV:75.0 pZIKV:95.0, pWNV:100 |
| rOD ratio ≥0.39 (DENV1 FL to WT VLP) | Overall: 96.6 (89.9–99.9) | 27.3 (1.0–40.7) |
| Subgroup: | pDENV1:100, sDENV:94.1 | naive:N/A, ZIKVwprDENV:0 pZIKV:0, pWNV:100 |
| WNV WT-VLP | Overall: 94.4 (87.0–98.3) | 91.4 (87.0–98.3) |
| Subgroup: | pWNV:94.4 | naive:98.4, ZIKVwprDENV:85.0 pZIKV:90.0, pDENV1:58.3, sDENV95.8 |
| WNV FL-VLP | Overall: 100 (100–100) | 93.7 (89.7–95.7) |
| Subgroup: | pWNV:100 | naive:98.5, ZIKVwprDENV:80.0 pZIKV:100, pDENV1:75.0, sDENV95.8 |
| rOD ratio ≥0.79 (WNV FL to WT VLP) | Overall: 100 (100–100) | 63.6 (35.2–78.1) |
| Subgroup: | pWNV:100 | naive:N/A, ZIKVwprDENV:33.0 pZIKV:100, pDENV1:60.0, sDENV:100 |

where FL: fusion loop; NA: not applicable; pDENV1: primary dengue virus type 1 infection; pWNV: primary West Nile virus infection; pZIKV: primary Zika virus infection; rOD: relative optical density; sDENV: secondary dengue virus infection.

For simplicity, the 95% CIs in the subgroup are not shown.

Compared to that of WT-VLP, the improved specificity by FL-VLP or FL/BCL-VLP is bolded.

Figure 4. Proposed algorithm of combined VLP IgG ELISA to distinguish three flavivirus infections. Based on the positivity to FL or FL/BCL mutant VLP of three flaviviruses (ZIKV, DENV and WNV), the samples that were negative to all three or positive to one of the mutant VLP could be flavivirus naive or primary DENV, pZIKV or pWNV infection. For samples that were positive to two or more mutant VLP, the rOD ratio of ZIKV mutant to WT VLP will be calculated to distinguish sDENV and ZIKVwprDENV infections.
pDENV1 and pWNV) comparable to that of WT-VLP (94.4–100%) (Table 2). Thus, we propose to use FL or FL/BCL mutant VLP for IgM ELISA. In contrast to the improved specificity of IgG ELISA by the rOD ratio (Table 1), the specificity of IgM ELISA was not improved by the rOD ratio (Table 2). This is probably due to relatively few samples that cross-reacted to both WT and mutant VLP in IgM ELISA, thus lowering the specificity of the rOD ratio.

Previously, we developed combined DENV1-4 and ZIKV NS1 IgG ELISA with a sensitivity/specificity of 100/82.9% and 94.5/91.9% to detect ZIKV and DENV1 infections, respectively [31]. We have also developed a multiplex NS1 IgG MIA with a sensitivity/specificity of 100/87.9%, 87.9/99.1% and 86.1/78.4% for ZIKV, DENV1 and WNV infections, respectively [32]. Compared with these two NS1-based IgG assays, our mutant VLP IgG ELISA had a sensitivity/specificity of 100/83.3%, 100/93.3% and 100/83.0% for ZIKV, DENV1 and WNV infections, respectively (Table 2), suggesting that E protein-based assays are more sensitive than NS1-based assays for DENV and WNV. The sensitivity of our ZIKV mutant VLP IgG ELISA (100%) was higher than or compatible to those reported previously (79 to 100%) using the Euroimmun ZIKV NS1 IgG ELISA kit or the blockade of binding ELISA [26–29]. Notably, the specificity of our ZIKV mutant VLP (83.3%) can be further improved to 92.2% by the rOD ratio of mutant to WT VLP (Table 2), which is comparable with that of the ZIKV NS1 blockade of binding ELISA (91.4–92.6%) [29]. Compared with a recent report of IgG ELISA based on mutant recombinant E proteins [37], which had a sensitivity/specificity, after pre-incubation with heterologous antigen, of 100/97.1% and 100/97.9% for ZIKV and DENV, respectively, our IgG ELISA using mutant VLP and rOD ratio had comparable sensitivity and specificity. In addition, our IgM ELISA using mutant VLP had a sensitivity and specificity higher than or comparable to those reported previously using mutant VLP or recombinant E proteins [34,37].

It is worth noting that our VLP-based ELISA can discriminate different ZIKV, DENV and WNV infections, whereas PRNT can only confirm pZIKV infection rather than those experiencing previous flavivirus infections [3]. A recent study suggested neutralizing antibody titres can distinguish ZIKV and DENV infections [56], nonetheless, the sensitivity and specificity of neutralizing antibody titres to discriminate various DENV and ZIKV infections, especially between sDENV and ZIKVwprDENV panels, remains to be determined. Neutralization tests are time-consuming and can be performed only in reference laboratories [3]. Compared with PRNT, our combined WT and mutant VLP IgG ELISA require less time (7 h vs. 5–6 days for PRNT) and less sample volume (6 µL vs. 128 µL for PRNT for 6 antigens or viruses). The VLP-based serological tests could be applied to serodiagnosis, blood screening and serosurveillance for three flavivirus infections, as well as retrospective study of ZIKV infection among pregnant women with CZS. They can also be developed into high-throughput formats such as MIA or rapid tests. These together would enhance our understanding of the epidemiology, pathogenesis and complications of ZIKV in flavivirus endemic regions [1,2].

This study has several limitations. First, in order to discriminate ZIKV and flaviviruses of other serocomplexes such as DENV, we only employed DENV1 VLP and pDENV1 panel to represent DENV1 and primary DENV infection samples, respectively. Although distinguishing DENV infections by different serotypes is beyond the scope of the study, future studies to include primary DENV infection panels from other serotypes are needed to validate these observations. Second, the sample size in each panel with RT-PCR-confirmed flavivirus infection is small and follow-up samples are limited. Despite two-time point samples for the pZIKV and ZIKVwprDENV panels were available, future studies involving larger sample size and more sequential samples are needed. Third, convalescent-phase samples from sDENV panel were not included the IgG ELISA due to insufficient volume. Whether our FL-mutant VLP can reduce the cross-reactivity of early convalescent-phase samples from sDENV infection remains to be investigated. Fourth, despite an algorithm based on our test to distinguish three flavivirus infections was proposed, more assays that can discriminate other medically important flaviviruses including JEV, YFV and tick-borne encephalitis virus (TBEV) remains to be investigated [57,58]. Additionally, including samples with well-documented repeated flavivirus infections are important for the assay development. As several flavivirus vaccines and vaccine trials have been employed in endemic regions, serological tests that can discriminate ZIKV infection and DENV, JEV, YFV or TBEV vaccinations remain to be exploited [57,58].

Acknowledgements

We thank Drs. E Harris at the University of California Berkeley and A. Balmaseda at the Ministry of Health, Managua, Nicaragua for providing samples from Nicaragua, and Dr. S. I. Stramer at the American Red Cross at Gaithersburg, Maryland for providing samples from blood donors.

Disclosure statement

No potential conflict of interest was reported by the author(s).
Funding
This work was supported by National Institute of Allergy and Infectious Diseases [grant numbers R01AI110769-01 (WKW), R21AI135292-01A1 (WKW)]; National Institute of General Medical Sciences [grant number P30GM114737]; Ministry of Health and Welfare [grant number MOHW109-TDU-B-212-114006 (JJT)] and National Health Research Institute, Taiwan [grant number NHRI-109-A1-MRCO-03202009 (JJT)].

ORCID
Wei-Kung Wang  http://orcid.org/0000-0002-6670-4663

References
[1] Lessler J, Chaisson LH, Kucirka LM, et al. Assessing the global threat from Zika virus. Science. 2016;353:aafl160.
[2] Musso D, Ko AI, Baud D. Zika virus infection – after the pandemic. N Engl J Med. 2019;381:1444–1457.
[3] Guidance for US Laboratories testing for Zika virus infection. From CDC’s website: http://www.cdc.gov/zika/laboratories/lab-guidance.html.
[4] Pierson TC, Diamond MS. Flaviviruses In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 747–794.
[5] Martin DA, Muth DA, Brown T, et al. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol. 2000;38:1823–1826.
[6] Johnson AJ, Martin DA, Karabatsos N, et al. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38:1827–1831.
[7] Modis Y, Ogata S, Clements D, et al. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427:313–319.
[8] Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631–6643.
[9] Crill WD, Hughes HR, Delorey MJ, et al. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4:e9491.
[10] Lai CY, Williams KL, Wu YC, et al. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis. 2013;7:e2451.
[11] Tsai WY, Lai CY, Wu YC, et al. High avidity and potent neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol. 2013;87:12562–12575.
[12] Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia. 2007. Emerg Infect Dis. 2008;14:1232–1239.
[13] Johnson BW, Kosoy O, Martin DA, et al. West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. Vector Borne Zoonotic Dis. 2005;5:137–145.
[14] van Meer MP, Möglng R, Klaasse J, et al. Re-evaluation of routine dengue virus serology in travelers in the era of Zika virus emergence. J Clin Virol. 2017;92:25–31.
[15] Felix AC, Souza NCS, Figueiredo WM, et al. Cross reactivity of commercial anti-dengue immunosassays in patients with acute Zika virus infection. J Med Virol. 2017;89:1477–1479.
[16] Ferlenghi I, Clarke M, Ruttan T, et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell. 2001;7:593–602.
[17] Schalich J, Allison SL, Stiasny K, et al. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J Virol. 1996;70:4549–4557.
[18] Lorenz IC, Kartenbeck J, Mezzacasa A, et al. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol. 2003;77:4370–4382.
[19] Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a nonfusious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol. 2001;75:4040–4047.
[20] Chiou SS, Crill WD, Chen LK, et al. Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol. 2008;15:825–835.
[21] Roberson JA, Crill WD, Chang GJ. Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol. 2007;45:3167–3174.
[22] de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA. 2012;109:7439–7444.
[23] Fibriansah G, Tan JL, Smith SA, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014;6:358–371.
[24] Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16:170–177.
[25] Teoh EP, Kuukkar O, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012;4:139ra83.
[26] Steinhagen K, Probst C, Radzimski C, et al. Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016;21:30426.
[27] Lustig Y, Zelena H, Venturi G, et al. Sensitivity and kinetics of an NS1-based Zika virus enzyme-linked immunosorbent assay in Zika virus-infected travelers from Israel, the Czech Republic, Italy, Belgium, Germany, and Chile. J Clin Microbiol. 2017;55:1894–1901.
[28] Safronetz D, Sloan A, Stein DR, et al. Evaluation of 5 commercially available Zika virus immunoassays. Emerg Infect Dis. 2017;23:1577–1580.
[29] Balmaseda A, Zambrana JV, Collado D, et al. Comparison of four serological methods and two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection. J Clin Microbiol. 2018;56:e01785–17.

[30] Tsai WY, Youn HH, Brites C, et al. Distinguishing secondary dengue virus infection from Zika virus infection with previous dengue by combination of three simple serological tests. Clin Infect Dis. 2017;65:1829–1836.

[31] Tyson J, Tsai WY, Tsai JJ, et al. Combination of non-structural protein 1-based enzyme-linked immunosorbent assays can detect and distinguish various dengue virus and Zika virus infections. J Clin Microbiol. 2019;57:e01464–18.

[32] Tyson J, Tsai WY, Tsai JJ, et al. A high-throughput and multiplex microsphere immunoassay based on non-structural protein 1 can discriminate three flavivirus infections. PLoS Negl Trop Dis. 2019;13:e0007649.

[33] Premkumar L, Collins M, Graham S, et al. Development of envelope protein antigens to serologically differentiate Zika virus infection from dengue virus infection. J Clin Microbiol. 2018;56:e01504–17.

[34] Chao DY, Whitney MT, Davis BS, et al. Comprehensive evaluation of differential serodiagnosis between Zika and dengue viral infections. J Clin Microbiol. 2019;57:e01506–18.

[35] Chabierski S, Barzon L, Papa A, et al. Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion loop. BMC Infect Dis. 2014;14:246.

[36] Rockstroh A, Barzon L, Pacenti M, et al. Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections. PLoS Negl Trop Dis. 2015;9:e0004218.

[37] Rockstroh A, Moges B, Barzon L, et al. Specific detection of dengue and Zika virus antibodies using envelope proteins with mutations in the conserved fusion loop. Emerg Microbes Infect. 2017;6:e49.

[38] Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17:1102–1108.

[39] Priyamvada L, Quicke KM, Hudson WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113:7852–7857.

[40] Bardina SV, Bunduc P, Tripathi S, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356:175–180.

[41] Rathore APS, Saron WAA, Lim T, et al. Maternal immunity and antibodies to dengue virus promote infection and Zika virus-induced microcephaly in fetuses. Sci Adv. 2019;5:eaav3208.

[42] McCracken MK, Gromowski GD, Friberg HL, et al. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog. 2017;13:e1006487.

[43] Pantoya P, Pérez-Guzmán EX, Rodríguez IV, et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun. 2017;8:15674.

[44] Halstead SB. Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg Infect Dis. 2017;23:569–573.

[45] Gordon A, Gresh L, Ojeda S, et al. Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. PLoS Med. 2019;16:e1002726.

[46] Rodríguez-Barraquer I, Costa F, Nascimento EJM, et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science. 2019;363:607–610.

[47] Kuan G, Gordon A, Avilés W, et al. The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol. 2009;170:120–129.

[48] Narvaez F, Gutierrez G, Perez MA, et al. Evaluation of the traditional and revised WHO classifications of dengue disease severity. PLoS Negl Trop Dis. 2011;5:e1397.

[49] Stramer SL, Fang CT, Foster GA, et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451–459.

[50] Wang WK, Chen HL, Yang CF, et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis. 2006;43:1032–1030.

[51] Tsai WY, Chen HL, Tsai JJ, et al. Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine. J Virol. 2018;92:e00556–18.

[52] Tsai JJ, Liu CK, Tsai WY, et al. Seroprevalence of dengue in two districts of Kaohsiung city after the largest dengue outbreak in Taiwan since world war II. PLoS Negl Trop Dis. 2018;12:e0006879.

[53] Klock HE, Lesley SA. The polymerase incomplete primer extension (PIPE) method applied to high-throughput cloning and site-directed mutagenesis. Methods Mol Biol. 2009;498:91–103.

[54] Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998;221:35–41.

[55] Dowd KA, DeMaso CR, Pelle RS, et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep. 2016;16:1485–1491.

[56] Montoya M, Collins M, Dejnirattisai W, et al. Longitudinal analysis of antibody cross-neutralization following Zika virus and dengue virus infection in Asia and the Americas. J Infect Dis. 2018;218:536–545.

[57] Munoza-Jordan JL. Diagnosis of Zika virus infections: challenges and opportunities. J Infect Dis. 2017;216(Suppl. 10):S951–S956.